Mutations in the Epidermal Growth Factor Receptor (EGFR) gene in triple-negative breast cancer: analysis by pyrosequencing in a series of 60 cases

被引：0
|
作者：
Carrera, R. [1 ]
Blanzquez, C. [1 ]
Escoda, M-R [1 ]
Saez, E. [1 ]
Palacio, L. [1 ]
Dalmau, E. [1 ]
Ramos, M-C [1 ]
Vazquez, J-A [1 ]
Andreu, F. J. [1 ]
机构：
[1] UDIAT Sabadell Hosp, Dept Pathol, Madrid, Spain
来源：
VIRCHOWS ARCHIV | 2014年 / 465卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-20-041
引用
收藏
页码：S324 / S324
页数：1
相关论文
共 50 条
  • [31] Germline Mutations in Triple-Negative Breast Cancer
    Hahnen, Eric
    Hauke, Jan
    Engel, Christoph
    Neidhardt, Guido
    Rhiem, Kerstin
    Schmutzler, Rita K.
    BREAST CARE, 2017, 12 (01) : 15 - 19
  • [32] P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency
    Shapira, Iuliana
    Lee, Annette
    Vora, Reena
    Budman, Daniel R.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 (02) : 284 - 292
  • [33] Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells
    Vacas, Eva
    Munoz-Moreno, Laura
    Valenzuela, Pedro L.
    Prieto, Juan C.
    Schally, Andrew V.
    Carmena, Maria J.
    Bajo, Ana M.
    PEPTIDES, 2016, 86 : 153 - 161
  • [34] Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer Promising Clinical Target or Only a Marker?
    Burness, Monika L.
    Grushko, Tatyana A.
    Olopade, Olufunmilayo I.
    CANCER JOURNAL, 2010, 16 (01): : 23 - 32
  • [35] Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
    Yam, Clinton
    Patel, Miral
    Hill, Holly A.
    Sun, Ryan
    Bassett, Roland L.
    Kong, Elisabeth
    Damodaran, Senthil
    Koenig, Kimberly B.
    Abouharb, Sausan
    Saleem, Sadia
    Bisen, Ajit K.
    Murthy, Rashmi K.
    Ramirez, David L.
    Rauch, Gaiane M.
    Adrada, Beatriz E.
    Candelaria, Rosalind P.
    Wang, Xiaoping
    Mittendorf, Elizabeth A.
    Thompson, Alastair M.
    White, Jason B.
    Ravenberg, Elizabeth E.
    Clayborn, Alyson R.
    Ding, Qing-Qing
    Booser, Daniel J.
    Oke, Oluchi
    Brewster, Abenaa M.
    Hortobagyi, Gabriel N.
    Ibrahim, Nuhad K.
    Litton, Jennifer K.
    Valero, Vicente
    Arun, Banu K.
    Tripathy, Debu
    Chang, Jeffrey T.
    Chen, Ken
    Korkut, Anil
    Moulder, Stacy L.
    Huo, Lei
    Lim, Bora
    Ueno, Naoto T.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (10): : 2823 - 2834
  • [36] Effect of mTOR inhibition on sensitivity of triple-negative breast cancer cells to epidermal growth factor inhibition
    Liu, T.
    Yacoub, R.
    Graham, T.
    Yang, L.
    Tighiouart, M.
    O'Regan, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor
    Greish, Khaled
    Nehoff, Hayley
    Bahman, Fatemah
    Pritchard, Tara
    Taurin, Sebastien
    JOURNAL OF DRUG TARGETING, 2019, 27 (08) : 903 - 916
  • [38] Epidermal Growth Factor Receptor (EGFR) Mutations, KRAS Mutations, and EGFR Gene Amplification by FISH on Cytology Specimens
    Leon, M. E.
    Villalona-Calero, M. A.
    Otterson, G. A.
    Zhao, W.
    LABORATORY INVESTIGATION, 2010, 90 : 99A - 99A
  • [39] Epidermal Growth Factor Receptor (EGFR) Mutations, KRAS Mutations, and EGFR Gene Amplification by FISH on Cytology Specimens
    Leon, M. E.
    Villalona-Calero, M. A.
    Otterson, G. A.
    Zhao, W.
    MODERN PATHOLOGY, 2010, 23 : 99A - 99A
  • [40] Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer (vol 13, pg 1356, 2014)
    Brand, Toni M.
    Iida, Mari
    Dunn, Emily F.
    Luthar, Neha
    Kostopoulos, Kellie T.
    Corrigan, Kelsey L.
    Wleklinski, Matthew J.
    Yang, David
    Wisinski, Kari B.
    Salgia, Ravi
    Wheeler, Deric L.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (04) : 868 - 868
12345